Kate Holloway

Kate Holloway currently provides expert consulting and contract modeling services as a Principal Scientist at Gfree Bio. She has extensive experience in the computer-aided design of novel medicines including contributions to the invention of ligands for > 60 different therapeutic targets during a 30+ year career at Merck. Successful design examples include: one of the first marketed HIV protease inhibitors, Crixivan® as well as a second-generation Hepatitis C protease inhibitor, grazoprevir, one component of Zepatier®. She has ~100 scientific publications and issued patents and, as a former chair of both the American Chemical Society Computers in Chemistry Division and the Gordon Research Conference on Computer-Aided Drug Design, she is actively involved in the structure-based design community.